Respiratory

Lupin gained FDA approval for varenicline tablets (0.5 mg and 1 mg) and launched its already-approved Turqoz (norgestrel and ethinyl estradiol) tablets USP, 0.3 mg/0.03 mg earlier this month.

Immunizations against influenza, COVID-19, and RSV are lower than they were this time last year, and hospitalizations have increased across all age groups.

A phase 4 study demonstrated that biologic therapies can control severe asthma while simultaneously helping patients minimize or eliminate harms associated with inhaled corticosteroids.

The NOTUS trial was shown to have successfully achieved its primary endpoint, demonstrating the notable efficacy of dupilumab in reducing exacerbations by 34% versus placebo in individuals with moderate-to-severe COPD showing evidence of type 2 inflammation.

The federal agencies said that they will continue to work closely with manufacturers to maintain the availability of the vaccines through the end of 2023 and early 2024 to meet the demand during the RSV season.

Maintaining a healthy diet before pregnancy was associated with a 10% reduced risk of children developing 'transient early' and 'persistent' wheeze patterns.

The capsule was developed by the pharmaceutical company Lupin and is a generic equivalent to Boehringer Ingelheim’s Spiriva HandiHaler.

A survey found that the proportion of primary care physicians who were unfamiliar with biologics and their eligibility criteria did not vary based on the number of asthma patients seen each month.

Understanding critical risk factors associated with the use of electronic nicotine delivery systems (ENDS) may help mitigate the harm dealt to youths by such devices.

Adverse effects of oral and inhaled corticosteroid use may impact quality of life for people with asthma.

Future disease-modifying interventions for COPD may greatly affect quality of life and survival.

Recognizing the challenges and needs associated with combating and preventing RSV may help reduce health care and patient burdens.

Stephen L. Foster, PharmD, FAPhA, FNAP, discussed the new vaccine and RSV prevalence at the National Community Pharmacists Association 2023 Convention and Expo.

Maternal immunization can prevent RSV in infants.

While baseline respiratory symptoms may increase the future risk of VTE in women, the study results did not find the same association in men.

Nonpharmaceutical interventions used during the COVID-19 pandemic may have affected the current epidemiology of respiratory infections in pediatric patients.

A refresher on best interventions for common respiratory disorders in children.

Although vitamin D supplementation is a low-cost treatment option, the optimal dosing strategy is currently unknown.

During a podcast hosted by Permanente Medicine, Sandra Fryhofer, MD, chair-elect of the Board of Trustees for the American Medical Association and a liaison to the CDC’s Advisory Committee on Immunization Practices, discussed the importance of vaccines for the fall and winter seasons.

As the Southern Hemisphere sees a mixed flu season, uncertainty looms for those in the North.

The phase 3 LIBERTY ASTHMA VOYAGE clinical trial was conducted with the purpose of investigating the effects of the investigational drug and discovering whether it would be a promising option.

A recent study found that lower vitamin k status was associated with higher rates of chronic obstructive lung disease, wheezing, and asthma.

Researchers believe a recent study shows how living in neighborhoods with high and very high levels of opportunity in early life is associated with lower asthma incidence in childhood.

E-cigarettes have garnered popularity since entering the market in 2006 as a potential aid for smoking cessation, but their use has been associated with increased adverse cardiovascular events.